These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38338672)

  • 1. In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of Cryopreservation.
    Jiang G; Neuber B; Hückelhoven-Krauss A; Höpken UE; Ding Y; Sedloev D; Wang L; Reichman A; Eberhardt F; Wermke M; Rehm A; Müller-Tidow C; Schmitt A; Schmitt M
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
    Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
    Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
    Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.
    Wang T; Yang Y; Ma L; Feng R; Li J; Zhang C; Bai J; Ding Y; Liu G; Wu F; Lu X; Feng S; Li Z; He T; Li J; Liu H
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39313307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity and exhaustion markers of chimeric antigen receptor T cells targeting BCMA in multiple myeloma cell lines between patients and healthy donors.
    Prasongtanakij S; Preedagasamzin S; Jittorntrum B; Anurathapan U; Puavilai T; Niparuck P; Chantrathammachart P; Piyajaroenkij T; Uaesoontrachoon K; Uchibori R; Ozawa K; Ohmine K; Hongeng S
    Eur J Haematol; 2024 Feb; 112(2):248-256. PubMed ID: 37222081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.
    Wang L; Gong W; Wang S; Neuber B; Sellner L; Schubert ML; Hückelhoven-Krauss A; Kunz A; Gern U; Michels B; Hinkelbein M; Mechler S; Richter P; Müller-Tidow C; Schmitt M; Schmitt A
    Cytotherapy; 2019 May; 21(5):566-578. PubMed ID: 30910382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Directed targeting of B-cell maturation antigen-specific CAR T cells by bioinformatic approaches: From in-silico to in-vitro.
    Moazzeni A; Kheirandish M; Khamisipour G; Rahbarizadeh F
    Immunobiology; 2023 May; 228(3):152376. PubMed ID: 37058845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells].
    Zhong MJ; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):804-811. PubMed ID: 31775477
    [No Abstract]   [Full Text] [Related]  

  • 10. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
    Pont MJ; Hill T; Cole GO; Abbott JJ; Kelliher J; Salter AI; Hudecek M; Comstock ML; Rajan A; Patel BKR; Voutsinas JM; Wu Q; Liu L; Cowan AJ; Wood BL; Green DJ; Riddell SR
    Blood; 2019 Nov; 134(19):1585-1597. PubMed ID: 31558469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
    Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
    Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma.
    Moles MW; Erdlei H; Menzel L; Massaro M; Fiori A; Bunse M; Schrimpf M; Gerlach K; Gudipati V; Reiser J; Mathavan K; Goodrich JP; Huppa JB; Krönke J; Valamehr B; Höpken UE; Rehm A
    Front Immunol; 2024; 15():1383136. PubMed ID: 38979422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
    Poels R; Drent E; Lameris R; Katsarou A; Themeli M; van der Vliet HJ; de Gruijl TD; van de Donk NWCJ; Mutis T
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells.
    Reichman A; Kunz A; Joedicke JJ; Höpken UE; Keib A; Neuber B; Sedloev D; Wang L; Jiang G; Hückelhoven-Krauss A; Eberhardt F; Müller-Tidow C; Wermke M; Rehm A; Schmitt M; Schmitt A
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.
    Camviel N; Wolf B; Croce G; Gfeller D; Zoete V; Arber C
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
    Ali SA; Shi V; Maric I; Wang M; Stroncek DF; Rose JJ; Brudno JN; Stetler-Stevenson M; Feldman SA; Hansen BG; Fellowes VS; Hakim FT; Gress RE; Kochenderfer JN
    Blood; 2016 Sep; 128(13):1688-700. PubMed ID: 27412889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy.
    Lee L; Lim WC; Galas-Filipowicz D; Fung K; Taylor J; Patel D; Akbar Z; Alvarez Mediavilla E; Wawrzyniecka P; Shome D; Reijmers RM; Gregg T; Wood L; Day W; Cerec V; Ferrari M; Thomas S; Cordoba S; Onuoha S; Khokhar N; Peddareddigari V; Al-Hajj M; Cavet J; Zweegman S; Rodriguez-Justo M; Youg K; Pule M; Popat R
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37399355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells.
    Wang Q; He F; He W; Huang Y; Zeng J; Zi F; Zheng J; Fei Y; Xu J; Song Y; Ye X; Lai R; Ye L; Zhu B
    Cell Immunol; 2021 May; 363():104342. PubMed ID: 33765541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma.
    Harush O; Asherie N; Kfir-Erenfeld S; Adler G; Barliya T; Assayag M; Gatt ME; Stepensky P; Cohen CJ
    Haematologica; 2022 Oct; 107(10):2395-2407. PubMed ID: 35354252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.